Phase 3 Recruiting Academic/Other
This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first started to nea…
Sponsor: NRG Oncology
NCT ID: NCT07441681
Sites in Minnesota: - Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
Phase 3 Recruiting Industry
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…
Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Minnesota: - Minnesota Oncology Hematology, PA ( Site 8003) — Edina, Minnesota
Phase 3 Recruiting Academic/Other
This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…
Sponsor: Mayo Clinic
NCT ID: NCT06915727
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Minnesota: - Local Institution - 2132 — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Minnesota: - HealthPartners Cancer Research Center — Saint Louis Park, Minnesota
- HealthPartners Cancer Research Center (Regions Hospital) — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Minnesota: - USOR Minnesota Oncology Hematology — Maplewood, Minnesota
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Minnesota: - Health Partners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
- Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of…
Sponsor: Gilead Sciences
NCT ID: NCT06657222
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Minnesota: - Mayo Clinic — Rochester, Minnesota
Phase 2 Recruiting Academic/Other
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course …
Sponsor: University of Minnesota
NCT ID: NCT05727761
Sites in Minnesota: - University of Minnesota — Minneapolis, Minnesota
- HealthPartners — Saint Paul, Minnesota
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating patients w…
Sponsor: Mayo Clinic
NCT ID: NCT07783581
Sites in Minnesota: - Mayo Clinic in Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Minnesota: - Allina Health Cancer Institute - Mercy Hospital — Coon Rapids, Minnesota
- Allina Health Cancer Institute - Abbott Northwestern Hospital — Minneapolis, Minnesota
- Allina Health Cancer Institute - United Hospital — Saint Paul, Minnesota
- Allina Health Cancer Institute — Saint Paul, Minnesota
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Minnesota: - Exelixis Clinical Site #68 — Rochester, Minnesota
Phase 1 Recruiting Industry
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…
Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…
Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Minnesota: - M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200 — Minneapolis, Minnesota
Phase 1 Recruiting Academic/Other
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion stu…
Sponsor: SparX Biotech(Jiangsu) Co., Ltd.
NCT ID: NCT06259552
Sites in Minnesota: - Mayo Clinic Rochester — Rochester, Minnesota
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
NA Recruiting Academic/Other
This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the FOLFOX re…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health - Baxter Clinic — Baxter, Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
- Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
- Minnesota Oncology - Burnsville — Burnsville, Minnesota
NA Recruiting Network
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Sponsor: GOG Foundation
NCT ID: NCT04831580
Sites in Minnesota: - Minnesota Oncology Hematology — Minneapolis, Minnesota
- M Health Fairview University of Minnesota Medical Center-East Bank Hospital — Minneapolis, Minnesota
- M Health Fairview University of Minnesota Medical Center-East Bank Hospital — Minneapolis, Minnesota
Phase 4 Recruiting Industry
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…
Sponsor: Pfizer
NCT ID: NCT06952660
Sites in Minnesota: - M Health Fairview Clinics and Specialty Center — Burnsville, Minnesota
- M Health Fairview Clinics and Surgery Center — Edina, Minnesota
- M Health Fairview Clinics and Surgery Center — Maple Grove, Minnesota
- M Health Fairview St. John's Hospital — Maplewood, Minnesota
- M Health Fairview Clinics and Surgery Center — Minneapolis, Minnesota
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Minnesota: - Massive Bio SYNERGY-AI site — Duluth, Minnesota
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Minnesota: - Riverwood Healthcare Center — Aitkin, Minnesota
- Essentia Health-St. Joseph's Medical Center — Brainerd, Minnesota
- Essentia Health - Duluth Clinic — Duluth, Minnesota
- St. Luke's Hospital of Duluth — Duluth, Minnesota
- Lake Region Healthcare — Fergus Falls, Minnesota